Recent studies have shown that ligands from the fibroblast growth factors (FGF) family reduce imatinib’s effect on GIST cells, and FGF2 and FGFR1 are highly expressed in all primary GIST samples. Here, FGFR1 is linked to gastrointestinal stromal tumor.